Clinical Trial Update: Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a conditioning regimen with alemtuzumab, fludarabine phosphate, and total-body irradiation followed by cyclosporine and mycophenolate m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Burkitt Lymphoma
• Chronic Myeloid Leukemia
• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)
• CELLCEPT (mycophenolate mofetil hydrochloride)
• Fludara (fludarabine)
• NEORAL (CYCLOSPORINE)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Status: COMPLETED | Results posted: 2017-05-30